Multiple endocrine neoplasia type 1 medical therapy

Revision as of 15:42, 21 July 2016 by Irfan Dotani (talk | contribs)
Jump to navigation Jump to search

Multiple endocrine neoplasia type 1 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 1 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple endocrine neoplasia type 1 medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 1 medical therapy

CDC on Multiple endocrine neoplasia type 1 medical therapy

Multiple endocrine neoplasia type 1 medical therapy in the news

Blogs on Multiple endocrine neoplasia type 1 medical therapy

Directions to Hospitals Treating Multiple endocrine neoplasia type 1

Risk calculators and risk factors for Multiple endocrine neoplasia type 1 medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [3]

Overview

Pharmacologic medical therapies for multiple endocrine neoplasia type 1 include cabergoline, somatostatin analogues, and H2- receptor blockers.

Management

  • Because the type of pancreatic endocrine cancer associated with multiple endocrine neoplasia type 1 can be difficult to recognize, difficult to treat, and slow to progress, there are different views about the value of surgery in managing these tumors.
  • One approach is to "watch and wait," using medical, or nonsurgical, treatments. According to this school of thought, pancreatic surgery has serious complications, so it should not be attempted unless it will cure a tumor or cure a hormone excess state.
  • Excessive release of certain hormones mainly gastrin from pancreatic endocrine cancer in multiple endocrine neoplasia type 1 needs to be treated, and medications are often effective in blocking the effects of these hormones.[1]
  • Cabergoline is the treatment of choice for prolactinomas.
  • Somatostatin analogues such as octreotide or lanreotide are used for the treatment of growth hormone secreting tumors.
  • H2-receptor antagonists and proton pump inhibitors are used to reduce the gastric output in gastrinomas.

References

  1. [1] Multiple Endocrine Neoplasia Type 1

Template:WS Template:WH